Literature DB >> 2868770

Bilateral malignant testicular germ cell cancer.

S Kristianslund, S D Fosså, K Kjellevold.   

Abstract

Twenty-six of approximately 1300 patients (1.9%) with unilateral testicular cancer developed a second primary germ cell cancer (seminoma 18; non-seminoma 8). Patients with previous seminoma had a significantly higher risk of developing a new seminoma than those with a previous non-seminoma. The diagnosis of second primary was made within 3 years of the first diagnosis in only 50% of the patients. In patients with a history of undescended and/or atrophic testes the interval significantly decreased between the diagnosis of the two testicular cancers. The prognosis of bilateral testicular cancer is generally good. Patients in whom the second testicular cancer is at clinical stage I (no metastases) at diagnosis can safely be observed without further treatment after orchiectomy. A patient with unilateral testicular cancer should be informed of the increased risk of developing a second primary germ cell tumour and should be encouraged to perform regular examination of the remaining testis. The need for life-long follow-up visits for patients with testicular cancer is questionable.

Entities:  

Mesh:

Year:  1986        PMID: 2868770     DOI: 10.1111/j.1464-410x.1986.tb05429.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  3 in total

1.  Sequential bilateral germ cell tumours of the testis.

Authors:  I Celebi; S Tekgül; H A Ozen; I Ozgü; D Remzi
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

2.  Testicular seminoma in a patient with pineal germinoma.

Authors:  D S Peat; J E Trowell
Journal:  J Clin Pathol       Date:  1994-08       Impact factor: 3.411

3.  Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy.

Authors:  Ch Theodore; M J Terrier-Lacombe; A Laplanche; G Benoit; K Fizazi; O Stamerra; P Wibault
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.